Experienced management team
with demonstrated track record. Our senior executive
officers have worked together for a number of years focused
on investing in properties for lease to tenants in the
life science industry. As a result, we have developed
relationships with numerous members of the scientific
community, life science investors, lenders and current
and prospective life science industry tenants.
Positive life
science industry trends. Based on the long-term
trends and projections for the life science industry,
we expect to see growth in revenues and research and
development spending from biotechnology and pharmaceutical
companies, scientific research institutions, government
agencies and other entities involved in the life science
industry over the foreseeable future, which should lead
to increasing demand for our properties.
High quality portfolio in high barrier-to-entry markets. We own interests in
69 properties, which include 112 buildings, well-located in all of our target markets, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey. We consider these properties to be high quality based on their strategic location in our target markets and significant level of improvements.
Highly scalable
business model. We intend to acquire assets with
triple-net leases, which will enable us to manage a large
property portfolio with a cost-effective management infrastructure.
Under some of the triple-net leases, we remain responsible
for the maintenance and repair of certain structural
components of the building.
